The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
Brenntag will supply Food & Nutrition customers in the United States and Canada with Lallemand’s renowned Nutrilife baking enzyme range
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Subscribe To Our Newsletter & Stay Updated
